ClinicalTrials.gg
Drug

Idelalisib clinical trials

Also written Zydelig®, CAL-101 and GS-1101.

studies test it
45
open now
2
in phase 3
9
first study started
2008

How each study uses idelalisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the idelalisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Jul 2014 · ZYDELIG · NDA 205858 (FDA, Drugs@FDA)
European Union
18 Sept 2014 · Zydelig · EMEA/H/C/003843 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Idelalisib
40
Phosphoinositide-3 Kinase Delta Inhibitor CAL-101
3

Brand

Zydelig®
31

Development codes

CAL-101
30
GS-1101
30

Studies by the year they started

45 studies that test it; most in 2015 (7)

Studies that test idelalisib, by start year
YearStudies
20081
20091
20102
20113
20126
20135
20144
20157
20165
20174
20182
20192
20221
20251
20261

Who runs them

Industry 28 · Other 17

Gilead Sciences (26) · Alliance for Clinical Trials in Oncology (2) · Dana-Farber Cancer Institute (2) · Calluna Pharma AS (1) · Mayo Clinic (1) · University of Maryland, Baltimore (1) · German CLL Study Group (1) · French Innovative Leukemia Organisation (1)

Often tested with

Tested in the same studies.

Rituximab (4) · Obinutuzumab (3) · Ibrutinib (2) · Dasatinib (2) · Ruxolitinib (2) · Pembrolizumab (1) · Tirabrutinib (1) · Pirtobrutinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Idelalisib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 1

Studies that test idelalisib.

Studies

Open first, then newest update. How each study uses idelalisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 45

See all 45 studies that test idelalisib →

Given beside what is tested · 8 — idelalisib is usual care or a partner of the new treatment
As the comparator · 6 — what is tested is compared with idelalisib

Codes

What other systems call idelalisib · ClinicalTrials.gg INT005724

  • MeSH (NLM) C552946idelalisibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) YG57I8T5M0IDELALISIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1544460Confirmed FDA, Wikidata
  • Wikidata Q5908266idelalisibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C78825IdelalisibOne source FDA
  • DrugBank DB09054One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.